LENZ
LENZ Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.07
−1.45%Next report
Analyst consensus
- Next report date
- Nov 4, 2026
- EPS estimate
- -$1.02
- Revenue estimate
- $4.5M
Latest reported
- Last report date
- Aug 11, 2026
- EPS actual
- -$1.02
- EPS estimate
- -$1.05
- Revenue actual
- $5.5M
- Revenue estimate
- $2.4M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -8.2%
- Revenue beats (12Q)
- 4
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $23
- PT range
- $7.00 – $38
- Analysts
- 2
1 Buy1 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 11, 2026 | -$1.05 | -$1.02 | Beat 2.86% | $5.5M |
| May 11, 2026 | -$1.10 | -$1.32 | Miss -20.00% | $1.9M |
| Mar 24, 2026 | -$0.91 | -$1.16 | Miss -27.47% | $1.6M |
| Nov 5, 2025 | -$0.67 | -$0.59 | Beat 11.94% | $12.5M |
| Jul 30, 2025 | -$0.58 | -$0.53 | Beat 8.62% | $5.0M |
| Mar 19, 2025 | -$0.42 | -$0.46 | Miss -9.52% | — |
| Aug 14, 2024 | -$0.49 | -$0.40 | Beat 18.37% | — |
| Feb 27, 2024 | -$0.13 | -$0.40 | Miss -207.69% | — |
| Nov 13, 2023 | -$0.25 | -$0.19 | Beat 24.00% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 4, 2026